These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 18669894)

  • 41. In vivo targeting of protein antigens to dendritic cells using anti-DEC-205 single chain antibody improves HIV Gag specific CD4
    Ngu LN; Nji NN; Ambada GE; Sagnia B; Sake CN; Tchadji JC; Njambe Priso GD; Lissom A; Tchouangueu TF; Manga Tebit D; Waffo AB; Park CG; Steinman RM; Überla K; Nchinda GW
    Immun Inflamm Dis; 2019 Jun; 7(2):55-67. PubMed ID: 28474788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extensive repertoire of membrane-bound and soluble dendritic cell-specific ICAM-3-grabbing nonintegrin 1 (DC-SIGN1) and DC-SIGN2 isoforms. Inter-individual variation in expression of DC-SIGN transcripts.
    Mummidi S; Catano G; Lam L; Hoefle A; Telles V; Begum K; Jimenez F; Ahuja SS; Ahuja SK
    J Biol Chem; 2001 Aug; 276(35):33196-212. PubMed ID: 11337487
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling.
    Lindsay RW; Darrah PA; Quinn KM; Wille-Reece U; Mattei LM; Iwasaki A; Kasturi SP; Pulendran B; Gall JG; Spies AG; Seder RA
    J Immunol; 2010 Aug; 185(3):1513-21. PubMed ID: 20610651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN.
    Cruz LJ; Tacken PJ; Pots JM; Torensma R; Buschow SI; Figdor CG
    Biomaterials; 2012 Jun; 33(16):4229-39. PubMed ID: 22410170
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cross-presentation of dead-cell-associated antigens by DNGR-1
    Balam S; Kesselring R; Eggenhofer E; Blaimer S; Evert K; Evert M; Schlitt HJ; Geissler EK; van Blijswijk J; Lee S; Reis e Sousa C; Brunner SM; Fichtner-Feigl S
    Eur J Immunol; 2020 Dec; 50(12):2041-2054. PubMed ID: 32640051
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
    van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
    Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Infection of dendritic cells (DCs), not DC-SIGN-mediated internalization of human immunodeficiency virus, is required for long-term transfer of virus to T cells.
    Burleigh L; Lozach PY; Schiffer C; Staropoli I; Pezo V; Porrot F; Canque B; Virelizier JL; Arenzana-Seisdedos F; Amara A
    J Virol; 2006 Mar; 80(6):2949-57. PubMed ID: 16501104
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development and Characterization of a Preclinical Model for the Evaluation of CD205-Mediated Antigen Delivery Therapeutics in Type 1 Diabetes.
    Schloss J; Ali R; Babad J; Guerrero-Ros I; Pongsachai J; He LZ; Keler T; DiLorenzo TP
    Immunohorizons; 2019 Jun; 3(6):236-253. PubMed ID: 31356169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting Antigens to Different Receptors on Conventional Type 1 Dendritic Cells Impacts the Immune Response.
    Fossum E; Tesfaye DY; Bobic S; Gudjonsson A; Braathen R; Lahoud MH; Caminschi I; Bogen B
    J Immunol; 2020 Aug; 205(3):661-673. PubMed ID: 32591401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased tubulointerstitial recruitment of human CD141(hi) CLEC9A(+) and CD1c(+) myeloid dendritic cell subsets in renal fibrosis and chronic kidney disease.
    Kassianos AJ; Wang X; Sampangi S; Muczynski K; Healy H; Wilkinson R
    Am J Physiol Renal Physiol; 2013 Nov; 305(10):F1391-401. PubMed ID: 24049150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation.
    Napoletano C; Zizzari IG; Rughetti A; Rahimi H; Irimura T; Clausen H; Wandall HH; Belleudi F; Bellati F; Pierelli L; Frati L; Nuti M
    Eur J Immunol; 2012 Apr; 42(4):936-45. PubMed ID: 22531918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Functional comparison of mouse CIRE/mouse DC-SIGN and human DC-SIGN.
    Caminschi I; Corbett AJ; Zahra C; Lahoud M; Lucas KM; Sofi M; Vremec D; Gramberg T; Pöhlmann S; Curtis J; Handman E; van Dommelen SL; Fleming P; Degli-Esposti MA; Shortman K; Wright MD
    Int Immunol; 2006 May; 18(5):741-53. PubMed ID: 16569675
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.
    Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F
    J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FLT3-ligand treatment of humanized mice results in the generation of large numbers of CD141+ and CD1c+ dendritic cells in vivo.
    Ding Y; Wilkinson A; Idris A; Fancke B; O'Keeffe M; Khalil D; Ju X; Lahoud MH; Caminschi I; Shortman K; Rodwell R; Vuckovic S; Radford KJ
    J Immunol; 2014 Feb; 192(4):1982-9. PubMed ID: 24453245
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
    Birkholz K; Schwenkert M; Kellner C; Gross S; Fey G; Schuler-Thurner B; Schuler G; Schaft N; Dörrie J
    Blood; 2010 Sep; 116(13):2277-85. PubMed ID: 20566893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Priming of CD8+ and CD4+ T cells in experimental leishmaniasis is initiated by different dendritic cell subtypes.
    Brewig N; Kissenpfennig A; Malissen B; Veit A; Bickert T; Fleischer B; Mostböck S; Ritter U
    J Immunol; 2009 Jan; 182(2):774-83. PubMed ID: 19124720
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mouse DC-SIGN/CD209a as Target for Antigen Delivery and Adaptive Immunity.
    Schetters STT; Kruijssen LJW; Crommentuijn MHW; Kalay H; Ochando J; den Haan JMM; Garcia-Vallejo JJ; van Kooyk Y
    Front Immunol; 2018; 9():990. PubMed ID: 29867967
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CLEC10A Is a Specific Marker for Human CD1c
    Heger L; Balk S; Lühr JJ; Heidkamp GF; Lehmann CHK; Hatscher L; Purbojo A; Hartmann A; Garcia-Martin F; Nishimura SI; Cesnjevar R; Nimmerjahn F; Dudziak D
    Front Immunol; 2018; 9():744. PubMed ID: 29755453
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clec9A
    Gilfillan CB; Kuhn S; Baey C; Hyde EJ; Yang J; Ruedl C; Ronchese F
    J Immunol; 2018 Apr; 200(8):2978-2986. PubMed ID: 29507107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.